Zevra Therapeutics, formerly KemPharm, has joined the Sleep Data Initiative, led by RARE-X and the Sleep Consortium, as a founding member.
The Sleep Data Initiative, a new data collection platform, aims to provide access to research-grade, patient-owned data to support the acceleration of research and treatment development for sleep disorders.
“Marking World Sleep Day today (March 17), we are proud to announce this important collaboration and our role as a founding member of this significant initiative to support acceleration and advancement of sleep research programs,” says Richard W. Pascoe, CEO of Zevra Therapeutics, in a press release. “The data being generated by our clinical program for KP1077, our novel therapy intended for the treatment of idiopathic hypersomnia, will support the research and development of effective treatments for rare sleep disorders through the use of this vital platform.”
RARE-X is a research program and data collection platform sponsored by Global Genes. The platform is currently supporting 83 disease communities, with about 58% of participants having reported sleep disturbance as a phenotype. Sleep Consortium is a not-for-profit organization working to support research and drug development for central disorders of hypersomnolence (CDH) and other related sleep disorders.
“As a founding member of the Sleep Data Initiative, Zevra Therapeutics recognizes the need for collaboration to develop creative solutions to improve the lives of patients with sleep disorders,” says Lindsay Jesteadt, PhD, CEO and co-founder of Sleep Consortium, in a press release. “Their funding support for the sleep data collection initiative demonstrates their commitment to the well-being of individuals living with CDH, both diagnosed and undiagnosed. This partnership supports the broader ecosystem of sleep health as we embark on unprecedented acceleration of research and treatment options.”
In addition, Zevra Therapeutics announced that patent number 11,505,537 from the United States Patent and Trademark Office was issued for its patent application entitled “Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same.”
The patent covers serdexmethylphenidate, the sole active pharmaceutical ingredient in KP1077, and expands Zevra Therapeutics’ intellectual property estate for the ingredient, which includes methods of use for methylphenidate conjugates to provide extended release of d-methylphenidate.
Photo 111136926 © Leowolfert | Dreamstime.com